Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | List with clinical criteria and/or conditions | Complete | ||
| Sutent | Sunitinib | Gastrointestinal stromal tumour (GIST) | List with clinical criteria and/or conditions | Complete | ||
| Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | ||
| Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
| Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
| Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | ||
| Alvesco | Ciclesonide | asthma | List | Complete | ||
| Denavir | Penciclovir | Herpes labialis (cold sores) | Do not list | Complete | ||
| Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | ||
| Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete |
Last Updated : April 27, 2024